+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 69Years
All Genders
ID07241234

Evaluating Safety, Tolerability, and Pharmacokinetics of AG-181 in Adults with Phenylketonuria

Led by Agios Pharmaceuticals, Inc. · Updated on 2026-10-28

20

Participants Needed

5

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and tolerability of AG-181 in adults with Phenylketonuria PKU, a genetic condition affecting metabolism. This Phase 1b, open-label study aims to understand how the drug behaves in the body and its effects on phenylalanine levels. The trial is sponsored by Agios Pharmaceuticals, Inc. and focuses on assessing adverse events and pharmacokinetics. Participants will receive AG-181 film-coated tablets daily from Day 1 to Day 28. The study includes two cohorts, both receiving the investigational drug without any placebo comparison. The treatment period is followed by monitoring for safety and drug concentration up to Day 42. The study does not involve randomization or blinding. During the study, participants will undergo regular evaluations including blood tests to measure drug levels and phenylalanine concentration. Researchers will monitor adverse events and serious adverse events related to the study drug up to 42 days. The total duration of participation covers treatment and follow-up assessments to gather comprehensive safety and pharmacodynamics data.

CONDITIONS

Brief Title

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria

Research Team

A

Agios Medical Affairs

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here